Details for Patent: 7,053,100

Title:	Therapeutic nucleosides
Abstract:	The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.
Inventor(s):	Liotta; Dennis C. (McDonough, GA)
Assignee:	Emory University, Inc. (Atlanta, GA)
Filing Date:	Jul 09, 2004
Application Number:	10/888,387
Claims:	1. A method of treating an HBV infection in a human comprising administering a pharmaceutical composition containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I) ##STR00005## or a pharmaceutically acceptable salt thereof to said HBV infected human, wherein the composition is suitable for rectal, nasal, topical, vaginal or parenteral administration. 2. The method of claim 1 wherein the composition is suitable for rectal administration. 3. The method of claim 1 wherein the composition is suitable for nasal administration. 4. The method of claim 1 wherein the composition is suitable for topical administration. 5. The method of claim 4 wherein the administration is transdermal, buccal or sublingual. 6. The method of claim 1 wherein the composition is suitable for vaginal administration. 7. The method of claim 1 wherein the composition is suitable for parenteral administration. 8. The method of claim 7 wherein the administration is subcutaneous, intramuscular, intravenous or intradermal. 9. The method of claim 7 wherein the composition comprises an isotonic sterile injection solution. 10. A method of treating an HBV infection in a human comprising administering a pharmaceutical composition suitable for oral administration containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I) ##STR00006## or a pharmaceutically acceptable salt thereof to said HBV infected human, wherein the composition further comprises a binder. 11. The method of claim 10 wherein the composition is in the form of a tablet. 12. The method of claim 10 wherein the binder is povidone. 13. The method of claim 10 wherein the binder is hydroxypropylmethyl cellulose. 14. The method of claim 10 wherein the composition further comprises a disintegrant. 15. The method of claim 14 wherein the disintegrant is cross-linked povidone. 16. The method of claim 14 wherein the disintegrant is cross-linked sodium carboxymethyl cellulose. 17. The method of claim 11 wherein the tablet comprises an enteric coating. 18. The method of claim 11 wherein the tablet comprises a buffering agent.